Omnicell Stock Price, News & Analysis (NASDAQ:OMCL)

$48.25 0.30 (0.63 %)
(As of 11/20/2017 04:12 AM ET)
Previous Close$47.95
Today's Range$47.40 - $48.55
52-Week Range$31.85 - $55.40
Volume294,000 shs
Average Volume255,265 shs
Market Capitalization$1.83024 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.7

About Omnicell (NASDAQ:OMCL)

Omnicell logoOmnicell, Inc. provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence. The Automation and Analytics segment is engaged in the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems and related software. The Medication Adherence segment includes the development, manufacturing and selling of consumable medication blister cards, packaging equipment, medication synchronization platform, and ancillary products and services. Its products are used to manage medication administration outside of the hospital setting and include medication adherence products sold under the brand name MTS, Surgichem, SureMed and the Omnicell brand.


Industry, Sector and Symbol:
  • Industry: Medical Software & Technology Services
  • Sub-Industry: Health Care Technology
  • Sector: Medical
  • Symbol: NASDAQ:OMCL
  • CUSIP: 68213N10
  • Web: www.omnicell.com
Debt:
  • Debt-to-Equity Ratio: 0.38%
  • Current Ratio: 1.53%
  • Quick Ratio: 1.08%
Price-To-Earnings:
  • Forward P/E Ratio: 402.08
  • P/E Growth: 25.53
Sales & Book Value:
  • Annual Sales: $692.62 million
  • Price / Sales: 2.64
  • Cash Flow: $1.66 per share
  • Price / Cash: 29.10
  • Book Value: $11.82 per share
  • Price / Book: 4.08
Profitability:
  • Trailing EPS: ($0.11)
  • Net Income: $600,000.00
  • Net Margins: -0.51%
  • Return on Equity: -0.79%
  • Return on Assets: -0.38%
Misc:
  • Employees: 2,444
  • Outstanding Shares: 37,930,000
 

Frequently Asked Questions for Omnicell (NASDAQ:OMCL)

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) announced its quarterly earnings data on Thursday, October, 26th. The company reported $0.42 earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of $0.42. The company earned $186.78 million during the quarter, compared to analysts' expectations of $192.45 million. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. The business's quarterly revenue was up 5.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.40 EPS. View Omnicell's Earnings History.

When will Omnicell make its next earnings announcement?

Omnicell is scheduled to release their next quarterly earnings announcement on Tuesday, February, 13th 2018. View Earnings Estimates for Omnicell.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell updated its fourth quarter earnings guidance on Thursday, October, 26th. The company provided earnings per share (EPS) guidance of $0.49-0.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.52. The company issued revenue guidance of $201-207 million, compared to the consensus revenue estimate of $210.22 million.

Where is Omnicell's stock going? Where will Omnicell's stock price be in 2017?

7 equities research analysts have issued 12-month target prices for Omnicell's shares. Their forecasts range from $40.00 to $67.00. On average, they expect Omnicell's share price to reach $54.86 in the next twelve months. View Analyst Ratings for Omnicell.

What are Wall Street analysts saying about Omnicell stock?

Here are some recent quotes from research analysts about Omnicell stock:

  • 1. According to Zacks Investment Research, "Omnicell exited third-quarter 2017 on a mixed note with earnings beating the Zacks Consensus Estimate and revenues missing the same. Also, weak margin scenario is a matter of concern. The company’s lowering of the high end of the full-year 2017 adjusted revenue guidanceis indicative of this overall dull scenario to remain. A tough competitive landscape also acts as a dampener. Over the last three months, Omnicell’s shares have been trading below the broader industry.However, on a positive note, the year-over-year increase in earnings and revenues was impressive. The company witnessed balanced growth across all its business lines in the quarter. We are encouraged to note that the company is working on product innovation through R&D. Over the recent past, Omnicell has been observed to gain consistently from series of product launches (the latest being XT Series Automated Supply Dispensing system) and strategic partnerships." (11/1/2017)
  • 2. Cantor Fitzgerald analysts commented, "Omnicell announced today that White River Health System in North Central Arkansas selected the company’s automated medication management solutions as well as their pharmacy management software." (7/25/2017)

Who are some of Omnicell's key competitors?

Who are Omnicell's key executives?

Omnicell's management team includes the folowing people:

  • Randall A. Lipps, Chairman of the Board, President, Chief Executive Officer (Age 59)
  • Peter J. Kuipers, Chief Financial Officer, Executive Vice President (Age 45)
  • Daniel S. Johnston, Executive Vice President, Chief Legal and Administrative Officer (Age 53)
  • J. Christopher Drew, Executive Vice President of Sales and Marketing for North American Automation (Age 51)
  • Nhat H. Ngo, Executive Vice President - Strategy and Business Development (Age 44)
  • Robin Gene Seim, Executive Vice President, Global Automation and Medication Adherence (Age 57)
  • Jorge R. Taborga, Executive Vice President - Engineering and Integration Management Office (Age 57)
  • James T. Judson, Lead Independent Director (Age 62)
  • Joanne B. Bauer, Independent Director (Age 61)
  • Vance B. Moore, Independent Director (Age 56)

Who owns Omnicell stock?

Omnicell's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Conestoga Capital Advisors LLC (4.32%), Dimensional Fund Advisors LP (4.14%), Bank of New York Mellon Corp (2.80%), Oak Ridge Investments LLC (2.74%), Eagle Asset Management Inc. (2.63%) and Janus Henderson Group PLC (2.13%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, James T Judson, Jorge R Taborga, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Sara J White. View Institutional Ownership Trends for Omnicell.

Who sold Omnicell stock? Who is selling Omnicell stock?

Omnicell's stock was sold by a variety of institutional investors in the last quarter, including Oak Ridge Investments LLC, Janus Henderson Group PLC, Westfield Capital Management Co. LP, Wells Fargo & Company MN, Bank of New York Mellon Corp, Mesirow Financial Investment Management Equity Management, Cramer Rosenthal Mcglynn LLC and Systematic Financial Management LP. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, James T Judson, Jorge R Taborga, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Sara J White. View Insider Buying and Selling for Omnicell.

Who bought Omnicell stock? Who is buying Omnicell stock?

Omnicell's stock was purchased by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Pier Capital LLC, Russell Investments Group Ltd., EAM Investors LLC, Axiom International Investors LLC DE, WINTON GROUP Ltd, Fisher Asset Management LLC and Kornitzer Capital Management Inc. KS. View Insider Buying and Selling for Omnicell.

How do I buy Omnicell stock?

Shares of Omnicell can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Omnicell's stock price today?

One share of Omnicell stock can currently be purchased for approximately $48.25.

How big of a company is Omnicell?

Omnicell has a market capitalization of $1.83024 billion and generates $692.62 million in revenue each year. The company earns $600,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Omnicell employs 2,444 workers across the globe.

How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]


MarketBeat Community Rating for Omnicell (NASDAQ OMCL)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  241 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  380
MarketBeat's community ratings are surveys of what our community members think about Omnicell and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Omnicell (NASDAQ:OMCL)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 6 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $54.86 (13.69% upside)

Consensus Price Target History for Omnicell (NASDAQ:OMCL)

Price Target History for Omnicell (NASDAQ:OMCL)

Analysts' Ratings History for Omnicell (NASDAQ:OMCL)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/30/2017Craig HallumReiterated RatingBuy$52.00 -> $62.00N/AView Rating Details
10/27/2017Cantor FitzgeraldBoost Price TargetOverweight$58.00N/AView Rating Details
10/19/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$55.00N/AView Rating Details
9/5/2017Benchmark Co.Boost Price TargetBuy -> Buy$55.00 -> $67.00MediumView Rating Details
7/30/2017Piper Jaffray CompaniesReiterated RatingHold$40.00MediumView Rating Details
7/28/2017Dougherty & CoBoost Price TargetBuy$45.00 -> $49.00HighView Rating Details
4/26/2017CIBCBoost Price TargetOutperform$43.00 -> $53.00LowView Rating Details
9/8/2016SidotiDowngradeBuy -> Neutral$43.00N/AView Rating Details
7/29/2016FBR & CoBoost Price TargetOutperform$40.00 -> $41.00N/AView Rating Details
3/21/2016Topeka Capital MarketsLower Price TargetBuy$38.00 -> $37.00N/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Omnicell (NASDAQ:OMCL)

Earnings by Quarter for Omnicell (NASDAQ:OMCL)

Earnings History by Quarter for Omnicell (NASDAQ OMCL)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/13/2018$0.52N/AView Earnings Details
10/26/2017Q3 2017$0.42$0.42$192.45 million$186.78 millionViewN/AView Earnings Details
7/27/2017Q2 2017$0.02$0.02$174.08 million$180.90 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.30)$0.06$152.63 million$150.90 millionViewListenView Earnings Details
2/15/2017Q4 2016$0.41$0.37$179.28 million$171.97 millionViewListenView Earnings Details
10/27/2016Q316$0.41$0.40$179.75 million$179.40 millionViewListenView Earnings Details
7/28/2016Q216$0.32$0.38$170.89 million$175.60 millionViewListenView Earnings Details
4/28/2016Q116$0.26$0.35$167.18 million$171.00 millionViewListenView Earnings Details
2/4/2016Q415$0.39$0.40$126.89 million$130.30 millionViewListenView Earnings Details
10/29/2015Q315$0.36$0.36$128.50 million$125.20 millionViewListenView Earnings Details
7/30/2015Q215$0.32$0.28$121.35 million$112.80 millionViewListenView Earnings Details
4/30/2015Q115$0.23$0.29$112.00 million$16.20 millionViewN/AView Earnings Details
2/3/2015Q414$0.33$0.39$114.65 million$121.50 millionViewListenView Earnings Details
10/30/2014Q314$0.31$0.30$106.10 million$112.50 millionViewListenView Earnings Details
7/31/2014Q214$0.29$0.30$103.23 million$105.10 millionViewListenView Earnings Details
5/1/2014Q114$0.24$0.26$97.49 million$101.80 millionViewListenView Earnings Details
2/4/2014Q413$0.28$0.29$101.13 million$105.80 millionViewListenView Earnings Details
10/31/2013Q313$0.28$0.31$94.96 million$94.03 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.25$0.27$92.42 million$93.70 millionViewN/AView Earnings Details
5/2/2013Q1 2013$0.19$0.21$87.20 million$87.11 millionViewN/AView Earnings Details
1/31/2013Q4 2012$0.25$0.25$87.31 million$90.16 millionViewN/AView Earnings Details
10/25/2012$0.22$0.29ViewN/AView Earnings Details
8/1/2012$0.18$0.20ViewN/AView Earnings Details
5/2/2012$0.13$0.13ViewN/AView Earnings Details
1/26/2012$0.16$0.19ViewN/AView Earnings Details
10/27/2011$0.16$0.16ViewN/AView Earnings Details
7/28/2011$0.13$0.15ViewN/AView Earnings Details
5/2/2011$0.10$0.11ViewN/AView Earnings Details
1/27/2011$0.12$0.11ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Omnicell (NASDAQ:OMCL)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171$0.12$0.12$0.12
Q4 20171$0.32$0.32$0.32
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Omnicell (NASDAQ:OMCL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Omnicell (NASDAQ OMCL)

Insider Ownership Percentage: 3.77%
Institutional Ownership Percentage: 97.93%
Insider Trades by Quarter for Omnicell (NASDAQ:OMCL)
Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Insider Trades by Quarter for Omnicell (NASDAQ OMCL)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/17/2017Dan S JohnstonEVPSell14,613$47.81$698,647.53View SEC Filing  
11/17/2017Peter J KuipersVPSell4,724$47.74$225,523.76View SEC Filing  
11/6/2017Jorge R TaborgaVPSell6,295$48.69$306,503.55View SEC Filing  
10/2/2017Peter J KuipersVPSell3,532$50.96$179,990.72View SEC Filing  
9/15/2017Robin Gene SeimEVPSell9,780$48.97$478,926.60View SEC Filing  
9/5/2017Gary S. PetersmeyerDirectorSell1,000$51.73$51,730.00View SEC Filing  
9/1/2017Randall A. LippsChairmanSell10,625$52.00$552,500.00View SEC Filing  
8/18/2017Dan S JohnstonEVPSell16,400$48.86$801,304.00View SEC Filing  
8/15/2017Robin Gene SeimEVPSell15,109$50.86$768,443.74View SEC Filing  
8/9/2017Peter J KuipersVPSell18,054$50.31$908,296.74View SEC Filing  
8/8/2017J Christopher DrewVPSell11,375$51.16$581,945.00View SEC Filing  
8/7/2017Jorge R TaborgaVPSell20,719$50.98$1,056,254.62View SEC Filing  
8/1/2017Randall A LippsChairmanSell40,000$49.76$1,990,400.00View SEC Filing  
7/28/2017Randall A LippsChairmanSell37,500$46.00$1,725,000.00View SEC Filing  
6/19/2017Randall A LippsChairmanSell31,527$42.87$1,351,562.49View SEC Filing  
6/5/2017Randall A LippsChairmanSell9,900$43.00$425,700.00View SEC Filing  
5/26/2017James T JudsonDirectorSell12,148$41.50$504,142.00View SEC Filing  
5/25/2017Gary S PetersmeyerDirectorSell2,200$41.41$91,102.00View SEC Filing  
5/19/2017Dan S JohnstonEVPSell16,400$40.67$666,988.00View SEC Filing  
5/9/2017J Christopher DrewVPSell10,625$40.97$435,306.25View SEC Filing  
4/25/2017Randall A LippsChairmanSell18,200$41.00$746,200.00View SEC Filing  
3/10/2017Gary S PetersmeyerDirectorSell2,658$37.45$99,542.10View SEC Filing  
2/21/2017Sara J WhiteDirectorSell3,443$38.06$131,040.58View SEC Filing  
11/18/2016Dan S JohnstonEVPSell8,850$33.65$297,802.50View SEC Filing  
11/18/2016Jorge R TaborgaVPSell2,068$33.66$69,608.88View SEC Filing  
11/8/2016J Christopher DrewVPSell20,000$31.95$639,000.00View SEC Filing  
9/12/2016Gary S PetersmeyerDirectorSell2,000$37.98$75,960.00View SEC Filing  
9/8/2016Gary S PetersmeyerDirectorSell2,400$39.39$94,536.00View SEC Filing  
9/6/2016Gary S PetersmeyerDirectorSell2,000$39.02$78,040.00View SEC Filing  
9/2/2016Gary S PetersmeyerDirectorSell3,000$38.52$115,560.00View SEC Filing  
8/19/2016Dan S JohnstonEVPSell8,850$36.93$326,830.50View SEC Filing  
8/19/2016Jorge R TaborgaVPSell1,778$36.92$65,643.76View SEC Filing  
8/11/2016Randall A LippsChairmanSell37,425$37.37$1,398,572.25View SEC Filing  
8/9/2016J Christopher DrewVPSell15,000$37.89$568,350.00View SEC Filing  
8/9/2016James T JudsonDirectorSell6,250$37.98$237,375.00View SEC Filing  
8/4/2016Gary S PetersmeyerDirectorSell8,750$37.84$331,100.00View SEC Filing  
7/29/2016Jorge R TaborgaVPSell10,023$40.00$400,920.00View SEC Filing  
7/6/2016Robin Gene SeimEVPSell5,302$34.75$184,244.50View SEC Filing  
7/1/2016Robin Gene SeimEVPSell3,645$35.00$127,575.00View SEC Filing  
6/6/2016Jorge R TaborgaVPSell25,979$33.00$857,307.00View SEC Filing  
5/24/2016Gary S PetersmeyerDirectorSell6,250$31.22$195,125.00View SEC Filing  
5/20/2016Dan S JohnstonEVPSell8,850$30.73$271,960.50View SEC Filing  
5/20/2016Jorge R TaborgaVPSell1,933$30.73$59,401.09View SEC Filing  
5/10/2016J Christopher DrewVPSell15,000$31.63$474,450.00View SEC Filing  
5/5/2016Sara J WhiteDirectorSell2,000$31.76$63,520.00View SEC Filing  
4/29/2016Robin Gene SeimEVPSell6,407$31.00$198,617.00View SEC Filing  
4/26/2016Jorge R TaborgaVPSell23,827$30.00$714,810.00View SEC Filing  
4/26/2016Robin Gene SeimEVPSell767$30.00$23,010.00View SEC Filing  
2/19/2016Dan S JohnstonEVPSell8,850$27.41$242,578.50View SEC Filing  
2/19/2016Jorge R TaborgaVPSell1,685$27.42$46,202.70View SEC Filing  
2/11/2016Randall A. LippsCEOSell40,000$27.81$1,112,400.00View SEC Filing  
2/9/2016J Christopher DrewVPSell15,000$27.57$413,550.00View SEC Filing  
12/18/2015Nhat H. NgoVPSell4,069$28.71$116,820.99View SEC Filing  
11/17/2015Dan S. JohnstonVPSell2,500$28.00$70,000.00View SEC Filing  
11/10/2015J Christopher DrewVPSell25,000$26.79$669,750.00View SEC Filing  
11/9/2015Dan S. JohnstonVPSell2,700$27.29$73,683.00View SEC Filing  
10/13/2015Gary S. PetersmeyerDirectorSell670$31.66$21,212.20View SEC Filing  
8/13/2015Robin Gene SeimCFOSell23,946$35.63$853,195.98View SEC Filing  
7/1/2015Robin Gene SeimCFOSell19,582$37.84$740,982.88View SEC Filing  
6/17/2015Nhat H NgoVPSell4,067$38.78$157,718.26View SEC Filing  
6/2/2015James T JudsonDirectorSell8,032$36.83$295,818.56View SEC Filing  
6/2/2015Nhat H NgoVPSell6,375$36.80$234,600.00View SEC Filing  
5/26/2015Sara J WhiteDirectorSell4,000$36.25$145,000.00View SEC Filing  
5/7/2015Dan S JohnstonVPSell7,715$34.25$264,238.75View SEC Filing  
2/12/2015J Christopher DrewVPSell25,000$34.62$865,500.00View SEC Filing  
2/6/2015Dan S JohnstonVPSell6,552$33.29$218,116.08View SEC Filing  
2/2/2015James T JudsonDirectorSell5,000$31.61$158,050.00View SEC Filing  
1/13/2015Gary S PetersmeyerDirectorSell670$31.31$20,977.70View SEC Filing  
1/2/2015James T JudsonDirectorSell5,000$32.36$161,800.00View SEC Filing  
1/2/2015Robin Gene SeimCFOSell1,948$32.36$63,037.28View SEC Filing  
12/17/2014Marga Ortigas-WedekindVPSell4,080$32.20$131,376.00View SEC Filing  
12/15/2014Gary S PetersmeyerDirectorSell670$33.25$22,277.50View SEC Filing  
12/8/2014Nhat H NgoVPSell1,754$32.89$57,689.06View SEC Filing  
12/1/2014James T JudsonDirectorSell5,000$31.94$159,700.00View SEC Filing  
11/12/2014Randy D LindholmDirectorSell5,000$31.72$158,600.00View SEC Filing  
11/11/2014J Christopher DrewVPSell37,500$31.86$1,194,750.00View SEC Filing  
11/7/2014Dan S JohnstonVPSell27,625$31.74$876,817.50View SEC Filing  
11/3/2014James T JudsonDirectorSell5,000$32.27$161,350.00View SEC Filing  
10/3/2014Nhat H NgoVPSell2,275$28.00$63,700.00View SEC Filing  
10/1/2014James T JudsonDirectorSell5,000$27.02$135,100.00View SEC Filing  
9/15/2014Jorge R TaborgaVPSell944$26.37$24,893.28View SEC Filing  
9/15/2014Robin Gene SeimCFOSell9,347$26.32$246,013.04View SEC Filing  
9/2/2014James T JudsonDirectorSell5,000$28.18$140,900.00View SEC Filing  
9/2/2014Robin Gene SeimCFOSell27,500$28.19$775,225.00View SEC Filing  
8/26/2014Dan S JohnstonVPSell6,250$28.00$175,000.00View SEC Filing  
8/26/2014James T JudsonDirectorSell9,913$27.91$276,671.83View SEC Filing  
7/9/2014Robin Gene SeimCFOSell2,442$28.21$68,888.82View SEC Filing  
7/1/2014James T JudsonDirectorSell5,000$29.28$146,400.00View SEC Filing  
6/26/2014Marga Ortigas-WedekindVPSell2,961$28.17$83,411.37View SEC Filing  
6/25/2014Nhat H NgoVPSell2,274$28.00$63,672.00View SEC Filing  
6/17/2014Nhat H NgoVPSell1,420$27.70$39,334.00View SEC Filing  
6/10/2014Nhat H NgoVPSell1,964$26.38$51,810.32View SEC Filing  
6/2/2014Gary S PetersmeyerDirectorSell5,000$26.45$132,250.00View SEC Filing  
5/21/2014Gary PetersmeyerDirectorSell2,000$26.51$53,020.00View SEC Filing  
5/13/2014J Christopher DrewVPSell37,500$26.08$978,000.00View SEC Filing  
5/7/2014Dan JohnstonVPSell4,000$25.25$101,000.00View SEC Filing  
5/1/2014James JudsonDirectorSell5,000$26.24$131,200.00View SEC Filing  
4/8/2014Nhat NgoVPSell1,002$27.40$27,454.80View SEC Filing  
3/18/2014Marga Ortigas-WedekindVPSell5,880$30.00$176,400.00View SEC Filing  
3/18/2014Randall LippsCEOSell124,910$29.89$3,733,559.90View SEC Filing  
12/18/2013Nhat NgoVPSell1,462$24.43$35,716.66View SEC Filing  
12/18/2013Randall LippsCEOSell64,739$24.30$1,573,157.70View SEC Filing  
12/3/2013Dan JohnstonVPSell73,419$23.24$1,706,257.56View SEC Filing  
11/11/2013Randy LindholmDirectorSell3,587$23.00$82,501.00View SEC Filing  
11/7/2013Dan JohnstonVPSell8,000$22.99$183,920.00View SEC Filing  
10/23/2013Robin Gene SeimCFOSell7,664$24.50$187,768.00View SEC Filing  
10/21/2013Robin Gene SeimCFOSell9,349$23.76$222,132.24View SEC Filing  
10/1/2013James T JudsonDirectorSell5,000$23.66$118,300.00View SEC Filing  
9/24/2013Randall LippsCEOSell68,204$25.00$1,705,100.00View SEC Filing  
9/23/2013Marga Ortigas-WedekindVPSell4,000$25.00$100,000.00View SEC Filing  
9/23/2013Randall LippsCEOSell5,083$25.00$127,075.00View SEC Filing  
9/20/2013Robin Gene SeimCFOSell27,500$24.35$669,625.00View SEC Filing  
9/18/2013Randall LippsCEOSell64,453$23.67$1,525,602.51View SEC Filing  
9/4/2013Nhat H NgoVPSell7,362$24.00$176,688.00View SEC Filing  
9/3/2013James JudsonDirectorSell5,000$22.77$113,850.00View SEC Filing  
8/20/2013James JudsonDirectorSell11,724$22.74$266,603.76View SEC Filing  
8/13/2013J Christopher DrewVPSell20,000$22.83$456,600.00View SEC Filing  
8/12/2013Donald WegmillerDirectorSell34,976$22.87$799,901.12View SEC Filing  
8/7/2013Dan JohnstonVPSell8,000$22.92$183,360.00View SEC Filing  
8/6/2013Randall LippsCEOSell5,321$23.00$122,383.00View SEC Filing  
8/2/2013Randall A LippsCEOSell25,000$22.50$562,500.00View SEC Filing  
8/1/2013James JudsonDirectorSell5,000$21.00$105,000.00View SEC Filing  
7/19/2013Nhat H NgoVPSell41,875$21.00$879,375.00View SEC Filing  
7/19/2013Randall A LippsCEOSell5,080$21.00$106,680.00View SEC Filing  
7/1/2013James T JudsonDirectorSell5,000$20.46$102,300.00View SEC Filing  
7/1/2013Robin Gene SeimCFOSell13,032$20.42$266,113.44View SEC Filing  
6/28/2013Marga Ortigas-WedekindVPSell4,545$20.00$90,900.00View SEC Filing  
6/28/2013Randall A LippsCEOSell25,000$20.00$500,000.00View SEC Filing  
6/21/2013Nhat H NgoVPSell3,459$19.01$65,755.59View SEC Filing  
6/18/2013Randall A LippsCEOSell66,378$19.10$1,267,819.80View SEC Filing  
6/10/2013Randy D LindholmDirectorSell23,901$19.14$457,465.14View SEC Filing  
6/4/2013Robin Gene SeimCFOSell25,000$18.72$468,000.00View SEC Filing  
5/22/2013Gary S PetersmeyerDirectorSell2,750$18.10$49,775.00View SEC Filing  
5/16/2013J Christopher DrewVPSell26,000$18.69$485,940.00View SEC Filing  
5/14/2013J Christopher DrewVPSell26,000$18.45$479,700.00View SEC Filing  
5/10/2013Sara J WhiteDirectorSell7,200$18.50$133,200.00View SEC Filing  
5/7/2013Dan S JohnstonVPSell8,000$18.44$147,520.00View SEC Filing  
12/3/2012Gary S PetersmeyerDirectorSell1,359$15.17$20,616.03View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Omnicell (NASDAQ OMCL)

Source:
DateHeadline
Omnicell To Present At The 29th Annual Piper Jaffray Healthcare ConferenceOmnicell To Present At The 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 18 at 10:35 AM
Omnicell, Inc. (OMCL) VP Peter J. Kuipers Sells 4,724 SharesOmnicell, Inc. (OMCL) VP Peter J. Kuipers Sells 4,724 Shares
www.americanbankingnews.com - November 17 at 8:56 PM
Omnicell, Inc. (OMCL) EVP Sells $698,647.53 in StockOmnicell, Inc. (OMCL) EVP Sells $698,647.53 in Stock
www.americanbankingnews.com - November 17 at 8:11 PM
Earnings Growth Make Omnicell (OMCL) a BuyEarnings Growth Make Omnicell (OMCL) a Buy
investorplace.com - November 16 at 2:19 PM
Zacks: Analysts Expect Omnicell, Inc. (OMCL) Will Announce Quarterly Sales of $204.19 MillionZacks: Analysts Expect Omnicell, Inc. (OMCL) Will Announce Quarterly Sales of $204.19 Million
www.americanbankingnews.com - November 16 at 12:18 PM
Omnicell, Inc. (OMCL) Receives Consensus Recommendation of "Buy" from BrokeragesOmnicell, Inc. (OMCL) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 16 at 11:54 AM
Oversold Conditions For Omnicell (OMCL)Oversold Conditions For Omnicell (OMCL)
www.nasdaq.com - November 15 at 7:07 AM
Omnicell Supports Global Charity Mercy Ships by Donating Next Generation XT Series Equipment and FundsOmnicell Supports Global Charity Mercy Ships by Donating Next Generation XT Series Equipment and Funds
finance.yahoo.com - November 15 at 7:07 AM
Omnicell, Inc. (OMCL) Expected to Post Earnings of $0.52 Per ShareOmnicell, Inc. (OMCL) Expected to Post Earnings of $0.52 Per Share
www.americanbankingnews.com - November 14 at 9:50 AM
ETFs with exposure to Omnicell, Inc. : November 9, 2017ETFs with exposure to Omnicell, Inc. : November 9, 2017
finance.yahoo.com - November 12 at 11:17 AM
Compelling Earnings Growth Analytics Raise Ranking of Omnicell (OMCL) to Strong BuyCompelling Earnings Growth Analytics Raise Ranking of Omnicell (OMCL) to Strong Buy
investorplace.com - November 9 at 5:38 PM
Omnicell, Inc. :OMCL-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017Omnicell, Inc. :OMCL-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017
finance.yahoo.com - November 9 at 10:09 AM
Texas Childrens Hospital Implements Omnicell Performance Center and Upgrades Medication Management AutomationTexas Children's Hospital Implements Omnicell Performance Center and Upgrades Medication Management Automation
finance.yahoo.com - November 9 at 10:09 AM
Omnicell Launches New IVX Workflow Solution to Enhance Safety, Accuracy, and Efficiency in Sterile CompoundingOmnicell Launches New IVX Workflow Solution to Enhance Safety, Accuracy, and Efficiency in Sterile Compounding
finance.yahoo.com - November 7 at 8:10 AM
Omnicell, Inc. (OMCL) VP Sells $306,503.55 in StockOmnicell, Inc. (OMCL) VP Sells $306,503.55 in Stock
www.americanbankingnews.com - November 6 at 7:00 PM
Omnicells Higher Investments Drive Costs, Competition RifeOmnicell's Higher Investments Drive Costs, Competition Rife
www.nasdaq.com - November 4 at 8:24 AM
Omnicells Higher Investments Drive Costs, Competition RifeOmnicell's Higher Investments Drive Costs, Competition Rife
www.nasdaq.com - November 4 at 8:24 AM
Healthy Earnings Momentum Makes Omnicell (OMCL) a BuyHealthy Earnings Momentum Makes Omnicell (OMCL) a Buy
investorplace.com - November 2 at 2:21 PM
Stocks Showing Rising Market Leadership: Omnicell Earns 83 RS RatingStocks Showing Rising Market Leadership: Omnicell Earns 83 RS Rating
finance.yahoo.com - November 2 at 7:15 AM
Omnicell, Inc. (OMCL) Downgraded to "Strong Sell" at Zacks Investment ResearchOmnicell, Inc. (OMCL) Downgraded to "Strong Sell" at Zacks Investment Research
www.americanbankingnews.com - November 1 at 9:18 AM
Omnicell, Inc. breached its 50 day moving average in a Bearish Manner : OMCL-US : October 31, 2017Omnicell, Inc. breached its 50 day moving average in a Bearish Manner : OMCL-US : October 31, 2017
finance.yahoo.com - November 1 at 7:13 AM
Reviewing Cotiviti Holdings (COTV) and Omnicell (OMCL)Reviewing Cotiviti Holdings (COTV) and Omnicell (OMCL)
www.americanbankingnews.com - October 27 at 5:12 PM
Hackensack Meridian Health Expands Contract with Omnicell for Medication Management TechnologyHackensack Meridian Health Expands Contract with Omnicell for Medication Management Technology
finance.yahoo.com - October 27 at 9:09 AM
Omnicell Achieves Record Revenue in the Third Quarter 2017Omnicell Achieves Record Revenue in the Third Quarter 2017
finance.yahoo.com - October 27 at 9:09 AM
Omnicell beats 3Q profit forecastsOmnicell beats 3Q profit forecasts
finance.yahoo.com - October 27 at 9:09 AM
Edited Transcript of OMCL earnings conference call or presentation 26-Oct-17 8:30pm GMTEdited Transcript of OMCL earnings conference call or presentation 26-Oct-17 8:30pm GMT
finance.yahoo.com - October 27 at 9:09 AM
Omnicell, Inc. (OMCL) Releases  Earnings Results, Meets EstimatesOmnicell, Inc. (OMCL) Releases Earnings Results, Meets Estimates
www.americanbankingnews.com - October 26 at 9:26 PM
Omnicell, Inc. (OMCL) Releases Q4 Earnings GuidanceOmnicell, Inc. (OMCL) Releases Q4 Earnings Guidance
www.americanbankingnews.com - October 26 at 5:42 PM
Earnings Visibility Makes Omnicell (OMCL) a BuyEarnings Visibility Makes Omnicell (OMCL) a Buy
investorplace.com - October 26 at 2:06 PM
Omnicell Announces Annual Innovation Day For Analysts And InvestorsOmnicell Announces Annual Innovation Day For Analysts And Investors
finance.yahoo.com - October 25 at 8:35 AM
Riverside Medical Center Selects Omnicells Medication Management Solutions to Enhance Medication Safety and SecurityRiverside Medical Center Selects Omnicell's Medication Management Solutions to Enhance Medication Safety and Security
finance.yahoo.com - October 25 at 8:35 AM
Omnicell, Inc. (OMCL) Expected to Announce Earnings of $0.41 Per ShareOmnicell, Inc. (OMCL) Expected to Announce Earnings of $0.41 Per Share
www.americanbankingnews.com - October 24 at 8:30 PM
Head-To-Head Comparison: Medical Transcription Billing, Corp. (MTBC) vs. Omnicell (OMCL)Head-To-Head Comparison: Medical Transcription Billing, Corp. (MTBC) vs. Omnicell (OMCL)
www.americanbankingnews.com - October 24 at 10:44 AM
Omnicells VBM 200F Pharmacy Automation Has Global Customer Adoption Success in a Variety of Pharmacy SettingsOmnicell's VBM 200F Pharmacy Automation Has Global Customer Adoption Success in a Variety of Pharmacy Settings
finance.yahoo.com - October 24 at 8:01 AM
Omnicell, Inc. (OMCL) Receives Average Recommendation of "Buy" from BrokeragesOmnicell, Inc. (OMCL) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - October 22 at 2:50 PM
Omnicell to Release Third Quarter 2017 Earnings Results on October 26, 2017Omnicell to Release Third Quarter 2017 Earnings Results on October 26, 2017
finance.yahoo.com - October 20 at 7:10 AM
Omnicell, Inc. (OMCL) Receives "Buy" Rating from Oppenheimer Holdings, Inc.Omnicell, Inc. (OMCL) Receives "Buy" Rating from Oppenheimer Holdings, Inc.
www.americanbankingnews.com - October 19 at 9:38 PM
Solid Quant Score Keeps Omnicell (OMCL) a BuySolid Quant Score Keeps Omnicell (OMCL) a Buy
investorplace.com - October 19 at 2:24 PM
Omnicell, Inc. (OMCL) Scheduled to Post Earnings on WednesdayOmnicell, Inc. (OMCL) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - October 18 at 5:16 AM
Omnicell Announces Inaugural "Inspired by Care" AwardsOmnicell Announces Inaugural "Inspired by Care" Awards
finance.yahoo.com - October 13 at 7:45 AM
$191.88 Million in Sales Expected for Omnicell, Inc. (OMCL) This Quarter$191.88 Million in Sales Expected for Omnicell, Inc. (OMCL) This Quarter
www.americanbankingnews.com - October 7 at 1:04 AM
Analyzing Omnicell (OMCL) & The CompetitionAnalyzing Omnicell (OMCL) & The Competition
www.americanbankingnews.com - October 6 at 8:30 PM
$0.41 EPS Expected for Omnicell, Inc. (OMCL) This Quarter$0.41 EPS Expected for Omnicell, Inc. (OMCL) This Quarter
www.americanbankingnews.com - October 5 at 10:16 PM
Glens Falls Hospital Selects Omnicell Medication Management Solutions to ...Glens Falls Hospital Selects Omnicell Medication Management Solutions to ...
www.prnewswire.com - October 5 at 6:49 PM
Omnicell Reaches Analyst Target PriceOmnicell Reaches Analyst Target Price
www.thestreet.com - October 5 at 6:49 PM
Omnicell (OMCL) Retains Buy RankingOmnicell (OMCL) Retains Buy Ranking
investorplace.com - October 5 at 2:21 PM
Glens Falls Hospital Selects Omnicell Medication Management Solutions to Support Improved Quality of Care and Patient ExperienceGlens Falls Hospital Selects Omnicell Medication Management Solutions to Support Improved Quality of Care and Patient Experience
finance.yahoo.com - October 5 at 1:45 PM
Frost & Sullivan Names Omnicell as Global Smart Hospitals Pharmacy Automation Vendor Company of the YearFrost & Sullivan Names Omnicell as Global Smart Hospitals' Pharmacy Automation Vendor Company of the Year
finance.yahoo.com - October 5 at 1:45 PM
Head to Head Analysis: Omnicell (OMCL) versus Its PeersHead to Head Analysis: Omnicell (OMCL) versus Its Peers
www.americanbankingnews.com - October 4 at 6:04 PM
Omnicell, Inc. (OMCL) VP Sells $179,990.72 in StockOmnicell, Inc. (OMCL) VP Sells $179,990.72 in Stock
www.americanbankingnews.com - October 2 at 7:42 PM

Social Media

Financials

Chart

Omnicell (NASDAQ OMCL) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.